First analysis on Pembrolizumab-treated Danish Patients with metastatic melanoma

Mira Rodding Kjeldsen, Mikkel Højlund, Rasmus Mortensen, Katrine Lundby Højer, Ulrich Heide Køhler, Inge Marie Svane, Henrik Schmidt, Lars Bastholt

Research output: Contribution to conference without publisher/journalConference abstract for conferenceResearchpeer-review

Abstract

Background:
Pembrolizumab is a monoclonal antibody that binds to PD-1, and it constitutes the newest treatment strategy for metastatic melanoma.
PD-1 is expressed on antigen-stimulated T-cells and tumour cells often express PD-1 ligand (PD-L1). This interaction induces a blockade of the downstream signalling, thereby inhibiting T-cell proliferation.
Hereby tumour cells inhibits T-cell response, but by blocking PD-1/PD-L1 pathway the T-cells will proliferate and continue to fight tumour cells. Two anti-PD1 drugs are in approval process, Pembrolizumab (Merck MSD) and Nivolumab (BMS), .
Both drugs have shown efficacy that is superior to current standard treatment strategy with Ipilimumab(1, 2). We started using Pembrolizumab (expanded access program) January 2014 to patients with metastatic melanoma with relapse after Ipilimumab.
We present data on efficacy in pts treated with Pembrolizumab.

Methods:
Pts treated with Pembrolizumab January 2014 to 30.06.2015, were registered in a national database with the following parameters: Date of progression and death, best overall response, line of treatment, different possible prognostic markers at baseline, including WHO performance status, biomarkers and M-stage.

Results:
119 pts with Ipilimumab-refractory advanced melanoma, were treated with Pembrolizumab at 3 Danish centres from 01.01.2014 to cut-off at 30.06.2015.
Original languageEnglish
Publication date2015
Publication statusPublished - 2015
EventNordic Melanoma Meeting - Göteborg, Sweden
Duration: 2. Sept 20154. Sept 2015
Conference number: 11

Conference

ConferenceNordic Melanoma Meeting
Number11
Country/TerritorySweden
CityGöteborg
Period02/09/201504/09/2015

Cite this